GNOM news

Global X Genomics & Biotechnology · Biotechnology · United States · Genomics & Biotech Innovation

Stories about this fund's companies, ranked by fund weight and recency. Times are local.

24/7 Wall St. · 28 Oct 2026, 16:04 UTC
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher
6.7% of GNOM
Scienmag: Latest Science and Health News · 28 Oct 2026, 18:47 UTC
Nanopore Sequencing Delivers Full Pediatric Brain Tumor Workup in a Single
4.8% of GNOM
Investing.com · 28 Oct 2026, 14:08 UTC
Why is Twist Bioscience stock surging today? By Investing.com
4.0% of GNOM
The Wall Street Journal · 28 Oct 2026, 20:17 UTC
Here's Why Moderna's CEO Isn't Fazed by Its Cancer-Vaccine Selloff
3.3% of GNOM
Where to buy GNOM
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
Seeking Alpha · 28 Oct 2026, 20:19 UTC
10x Genomics: Atera Takes Off, But Valuation Flies Too High (NASDAQ:TXG) | Seeking Alpha
3.2% of GNOM
TheStreet · 28 Oct 2026, 19:33 UTC
Breakthrough cancer vaccine catches Wall Street's attention
3.3% of GNOM
Where to buy GNOM
- [Broker A]Visit ↗
- [Broker B]Visit ↗
[Affiliate and risk wording from the law firm]
wallstreet:online · 28 Oct 2026, 12:05 UTC
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
4.0% of GNOM
Quartz · 28 Oct 2026, 16:16 UTC
Best-selling drugs 2026: 7 of the top 10 by 2025 sales
3.5% of GNOM
Seeking Alpha · 28 Oct 2026, 16:22 UTC
Moderna: ESMO Answered The Science, Q3 Has To Answer The Money (NASDAQ:MRNA) | Seeking Alpha
3.3% of GNOM
Investing.com · 28 Oct 2026, 14:13 UTC
Why is Moderna stock rebounding today? By Investing.com
3.3% of GNOM
Seeking Alpha · 28 Oct 2026, 12:10 UTC
Fidelity Growth Company Fund Q3 2026 Commentary (FDGRX) | Seeking Alpha
3.3% of GNOM
24/7 Wall St. · 28 Oct 2026, 19:24 UTC
16% of Employers Are Thinking About Cutting Weight-Loss Drug Coverage
2.3% of GNOM
Seeking Alpha · 28 Oct 2026, 15:55 UTC
Pharma giants Merck, Eli Lilly face earnings health check (MRK:NYSE) | Seeking Alpha
2.3% of GNOM
The Manila times · 27 Oct 2026, 20:21 UTC
Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
4.0% of GNOM
Quartz · 28 Oct 2026, 14:15 UTC
New weight-loss drugs: what 6 drugmakers are testing
2.3% of GNOM
Benzinga · 28 Oct 2026, 13:25 UTC
Eli Lilly Says Retatrutide Delivers More Than Double Ozempic's Weight Loss in Late-Stage Diabetes Trial -
2.3% of GNOM
24/7 Wall St. · 28 Oct 2026, 12:14 UTC
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
2.3% of GNOM
Market Screener · 28 Oct 2026, 12:07 UTC
Eli Lilly And Company Announces Positive Topline Results From TRANSCEND-T2D-2 Phase 3 Trial Of Retatrutide In Adults With Type 2 Diabetes
2.3% of GNOM
Benzinga · 28 Oct 2026, 10:04 UTC
Top Wall Street Forecasters Revamp Eli Lilly Expectations Ahead Of Q3 Earnings - Eli Lilly (NYSE:LLY)
2.3% of GNOM
The Manila times · 28 Oct 2026, 20:27 UTC
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.6% of GNOM

GNOM news

Where to buy GNOM

Where to buy GNOM